Monte Rosa Therapeutics, Inc. (GLUE) Return on equity 2023–2025
Monte Rosa Therapeutics, Inc. (GLUE) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-31.2%FY2025 · since FY2023: -60.5% → -31.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -31.2% | +29.5 pp |
| FY2024 | -60.7% | -0.2 pp |
| FY2023 | -60.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GLUE financial trends
GLUE RevenueGLUE Net incomeGLUE Net marginGLUE Gross profitGLUE Gross marginGLUE Operating incomeGLUE Operating marginGLUE Operating cash flowGLUE Free cash flowGLUE Capital expendituresGLUE Stock buybacksGLUE Dividends paidGLUE Total assetsGLUE Total liabilitiesGLUE Shareholders’ equityGLUE overview →